BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26259878)

  • 1. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
    Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
    Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
    Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
    Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N
    Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
    Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
    Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loco-regional staging of malignant pleural mesothelioma by integrated
    Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
    Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
    Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
    Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
    Kawaguchi K; Taniguchi T; Usami N; Fukui T; Ishiguro F; Nakamura S; Yokoi K
    Gen Thorac Cardiovasc Surg; 2014 Mar; 62(3):157-62. PubMed ID: 24281913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
    Colin DJ; Bejuy O; Germain S; Triponez F; Serre-Beinier V
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
    Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
    Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.